SLC22A12 and metabolic syndrome: Accordingly, when mice are exposed to high PA (e.g., in metabolic syndrome), the action of URAT1 in cardiomyocytes is enhanced, and URAT1-selective inhibition has more potent effects in the HFD mouse heart than in the NFD mouse heart.